Expanded Access Using Allogeneic Bone-marrow Derived Human Mesenchymal Stem Cells (Allo-hMSC) for a Individual Parkinson's Disease Subject

NCT06798064 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-01-29

No results posted yet for this study

Summary

This is a expanded access use of allogeneic bone marrow-derived mesenchymal stem cells for a single subject with moderate Parkinson's disease that has progressed.

Conditions

  • Parkinson Disease

Interventions

BIOLOGICAL

Allogeneic bone marrow-derived mesenchymal stem cells

Sponsors & Collaborators

  • Mya Schiess

    lead OTHER

Principal Investigators

  • Mya Schiess, MD · The University of Texas Health Science Center, Houston

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06798064 on ClinicalTrials.gov